To identify proteins displaced from physical interaction with LSD1 following treatment of AML cells with OG86 (Oryzon Genomics compound #86; trans-N-((2-methoxypyridin-3-yl)methyl)-2-phenylcyclopropan-1-amine) which is a representative tranylcypromine-derivative inhibitor of LSD1, we used both Stable Isotope Labeling by Amino acids in cell Culture (SILAC) and Immunoprecipitation-Mass Spectrometry (IP-MS) as relative quantitation proteomics approaches (Fig. 1A) [2, 8]. The gene discussed is KDM1A; the disease is acute myeloid leukemia.